• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Yoshihiro Oka, Akihiro Tsuboi, +23 authors Haruo Sugiyama
  • Medicine, Biology
  • Proceedings of the National Academy of Sciences…
  • 2004 (First Publication: 21 September 2004)
  • The Wilms' tumor gene WT1 is overexpressed in leukemias and various types of solid tumors, and the WT1 protein was demonstrated to be an attractive target antigen for immunotherapy against theseExpand
  • Norihiro Kotani, Jianguo G Gu, Tomoya Isaji, Keiko Udaka, Naoyuki Taniguchi, Koichi Honke
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences
  • 2008 (First Publication: 27 May 2008)
  • Many plasma membrane-resident molecules cluster with other molecules to collaborate in a variety of biological events. We herein report a sensitive and simple method to identify components of cellExpand
  • Hirofumi Nishikawa, Yoshinori Taniguchi, +11 authors Yoshio Terada
  • Medicine
  • Kidney international
  • 2018 (First Publication: 11 December 2017)
  • IL-36, a newly named member of the IL-1 cytokine family, includes 3 isoforms, IL-36α, IL-36β, and IL-36γ, all of which bind to a heterodimer containing the IL-36 receptor (IL-36R). Little is knownExpand
  • Akihiro Tsuboi, Yoshihiro Oka, +17 authors Haruo Sugiyama
  • Biology, Medicine
  • Cancer Immunology, Immunotherapy
  • 2002 (First Publication: 1 December 2002)
  • Abstract. The Wilms' tumor gene WT1 is overexpressed in most types of leukemias and various kinds of solid tumors, including lung and breast cancer, and participates in leukemogenesis andExpand
  • Satoshi Morita, Yoshihiro Oka, +21 authors Junichi Sakamoto
  • Medicine
  • Japanese journal of clinical oncology
  • 2006 (First Publication: 1 April 2006)
  • OBJECTIVE We conducted a phase I study to investigate the safety of a weekly WT1 tumor vaccine therapy in patients with solid tumors that had been refractory to all other anti-cancer therapies. Expand